Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers.

× No keyword cloud information.

1 in total

1. Commercial interest waxes for IGF-1 blockers.

Authors: Randy Osborne
Journal: Nat Biotechnol Date: 2008-07 Impact factor: 54.908

1 in total

7 in total

Review 1. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

Authors: Rashmi R Shah
Journal: Drug Saf Date: 2017-03 Impact factor: 5.606

2. Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis.

Authors: Lei Li; Jiang-Chao Li; Hong Yang; Xu Zhang; Lu-Lu Liu; Yan Li; Ting-Ting Zeng; Ying-Hui Zhu; Xiao-Dong Li; Yan Li; Dan Xie; Li Fu; Xin-Yuan Guan
Journal: Proc Natl Acad Sci U S A Date: 2018-08-29 Impact factor: 11.205

3. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.

Authors: Juergen M Schanzer; Katharina Wartha; Ekkehard Moessner; Ralf J Hosse; Samuel Moser; Rebecca Croasdale; Halina Trochanowska; Cuiying Shao; Peng Wang; Lei Shi; Tina Weinzierl; Natascha Rieder; Marina Bacac; Carola H Ries; Hubert Kettenberger; Tilman Schlothauer; Thomas Friess; Pablo Umana; Christian Klein
Journal: MAbs Date: 2016-03-16 Impact factor: 5.857

Review 4. Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future.

Authors: Zhengyang Zhu; Chaoyou Fang; Houshi Xu; Ling Yuan; Yichao Du; Yunjia Ni; Yuanzhi Xu; Anwen Shao; Anke Zhang; Meiqing Lou
Journal: Front Oncol Date: 2022-08-15 Impact factor: 5.738

5. Modeling the Insulin-Like Growth Factor System in Articular Cartilage.

Authors: Lihai Zhang; David W Smith; Bruce S Gardiner; Alan J Grodzinsky
Journal: PLoS One Date: 2013-06-26 Impact factor: 3.240

6. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.

Authors: Peter M Anderson; Stefan S Bielack; Richard G Gorlick; Keith Skubitz; Najat C Daw; Cynthia E Herzog; Odd R Monge; Alvaro Lassaletta; Erica Boldrini; Zsuzanna Pápai; Joseph Rubino; Kumudu Pathiraja; Darcy A Hille; Mark Ayers; Siu-Long Yao; Michael Nebozhyn; Brian Lu; David Mauro
Journal: Pediatr Blood Cancer Date: 2016-06-30 Impact factor: 3.167

7. Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer.

Authors: Viswas Raja Solomon; Elahe Alizadeh; Wendy Bernhard; Amal Makhlouf; Siddesh V Hartimath; Wayne Hill; Ayman El-Sayed; Kris Barreto; Clarence Ronald Geyer; Humphrey Fonge
Journal: Sci Rep Date: 2020-10-29 Impact factor: 4.379

7 in total